Literature DB >> 2878367

Cancer chemotherapy. Progress in understanding multidrug resistance.

G R Stark.   

Abstract

Mesh：

Substances：

Year:  1986        PMID： 2878367     DOI： 10.1038/324407a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

1.  Cross-resistance to polyene and azole drugs in Cryptococcus neoformans.

Authors:  T Joseph-Horne; D Hollomon; R S Loeffler; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

2.  Investigation of the Sterol Composition and Azole Resistance in Field Isolates of Septoria tritici.

Authors:  T Joseph-Horne; D Hollomon; N Manning; S L Kelly
Journal:  Appl Environ Microbiol       Date:  1996-01       Impact factor: 4.792

3.  PDR3, a new yeast regulatory gene, is homologous to PDR1 and controls the multidrug resistance phenomenon.

Authors:  T Delaveau; A Delahodde; E Carvajal; J Subik; C Jacq
Journal:  Mol Gen Genet       Date:  1994-09-01

4.  The export of the DNA replication inhibitor Microcin B17 provides immunity for the host cell.

Authors:  M C Garrido; M Herrero; R Kolter; F Moreno
Journal:  EMBO J       Date:  1988-06       Impact factor: 11.598

5.  Pre-clinical studies of a novel anti-mitotic agent, amphethinile.

Authors:  A T McGown; C Ewen; D B Smith; B W Fox
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

6.  The effects of multifunctional MiR-122-loaded graphene-gold composites on drug-resistant liver cancer.

Authors:  Yi Yuan; Yaqin Zhang; Bin Liu; Heming Wu; Yanjun Kang; Ming Li; Xin Zeng; Nongyue He; Gen Zhang
Journal:  J Nanobiotechnology       Date:  2015-02-12       Impact factor: 10.435

Review 7.  Research Progress Based on Regulation of Tumor Microenvironment Redox and Drug-Loaded Metal-Organic Frameworks.

Authors:  Tong Xu
Journal:  Oxid Med Cell Longev       Date:  2022-07-22       Impact factor: 7.310

8.  Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives.

Authors:  C Gavériaux; D Boesch; J J Boelsterli; P Bollinger; M K Eberle; P Hiestand; T Payne; R Traber; R Wenger; F Loor
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.